• locally advanced NSCLC - maintenance (M)
• laNSCLC - M - all population 1
• laNSCLC - M - EGFR mutant

 

• HER inhibitor
• EGFR inhibitor
• erlotinib based treatment
• erlotinib alone
• immune chekpoint inhibitors
• anti-PD-(L)1
• durvalumab based treatment
• durvalumab alone
• sugemalimab based treatment
• Sugemalimab

• versus all
• vs chemotherapy
• vs non platinum-based chemotherapy
• vs topoisomerase I inhibitor
• vs irinotecan
• vs irinotecan plus platin
• vs non active control
• vs placebo

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)